At the Alzheimer’s Association International Conference, July 2017, Dr. Randall Bateman presented data showing that amyloid beta (Abeta) concentrations can be measured reliably using mass spectrometry, and that the ratio between two of the Abeta isoforms measured in plasma can be used to indicate if a person has brain amyloidosis – a hallmark pathology observed in patients with Alzheimer’s disease.
On May 2nd 2017, the NIH Director, Sir Francis Collins, highlighted the recently published study by Washington University scientists in collaboration with C2N Diagnostics, showing that the protein tau increases in blood after peripheral administration of an anti-tau antibody. The study found that, in mice, the level of tau increase in blood correlated with the tau pathology in the brain, raising the possibility that this technology could be used to develop a blood test for brain tau pathology.
A new study published in Science Translational Medicine found that administration of antibody against the tau protein, leads to increases in tau in plasma that correlate with the levels of tau in the brain.
In a 9 page report Medtech Insight outlines the current state of the field of Alzheimer’s disease diagnostic.
Read the report: “Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty“.…
Read More →